Inhalation Sciences is a Swedish, cutting-edge CRO specializing in inhaled drug development for NCE's, generics, and biologics. Our services enable data-driven decision-making early in development, helping minimize risk, reduce timelines, and lower costs. Unique deliverables enabled by our proprietary PreciseInhale® technology platform; • Precision dosing of aerosol • Unmatched precision in pharmacokinetic data - correlating to in-human results • Unprecedented clinical predictability • Significantly de-risking inhaled drug development • Reduced use of API and animals Our multidisciplinary team brings extensive contract research experience in inhalation drug development. Our founder and CSO, Per Gerde is a recognized world authority and Associate Professor of Inhalation Toxicology at the Institute of Environmental Medicine, Karolinska Institute in Sweden. Visit our website: http://www.inhalation.se/ Visit our labs: Kliniskt Forskningscentrum KFC Novum plan 6 hiss A Hälsovägen 7 141 57 Huddinge, Sweden Visitor entrance, Blickagången 6, elevator E, level 6
Looking for a particular Inhalation Sciences Sweden AB employee's phone or email?
The Inhalation Sciences Sweden AB annual revenue was $1 million in 2026.
Pontus Nobreus is the CEO of Inhalation Sciences Sweden AB.
9 people are employed at Inhalation Sciences Sweden AB.
The NAICS codes for Inhalation Sciences Sweden AB are [54171, 333, 541713, 5417, 54, 541, 33].
The SIC codes for Inhalation Sciences Sweden AB are [873, 87, 358, 35].